1. Experience with the potassium binder patiromer in hyperkalaemia management in heart failure patients in real life
- Author
-
Alberto Esteban‐Fernández, Carolina Ortiz Cortés, Silvia López‐Fernández, Alejandro Recio Mayoral, Francisco Javier Camacho Jurado, Inés Gómez Otero, María Molina, Luis Almenar Bonet, and Raquel López‐Vilella
- Subjects
Hyperkalaemia ,Potassium binders ,Patiromer ,Heart failure ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Abstract Aims Hyperkalaemia (HK) is common in heart failure (HF) patients, related to renal dysfunction and medical treatment. It limits medical therapy optimization, which impacts prognosis. New potassium (K) binders help control HK, allowing better medical management of HF. Methods and results A retrospective multicentre register included all outpatients with HF and HK (K ≥ 5.1 mEq/L) treated with patiromer according to current recommendations. We evaluated analytic and clinical parameters before starting the treatment and at 7, 30 and 90 days, as well as adverse events related to patiromer and treatment optimization. We included 74 patients (71.6% male) with a mean age of 70.8 years (SD 9.2). Sixty‐seven patients (90.5%) presented HK in the previous year. Forty patients (54.1%) underwent down‐titration of a renin–angiotensin–aldosterone inhibitor (RAASi) or a mineralocorticoid receptor antagonist (MRA), and 27 (36.5%) stopped any of them due to HK. Initial K was 5.5 mEq/L (SD 0.6), with a significantly reduction at 7 days (4.9 mEq/L (SD 0.8); P
- Published
- 2022
- Full Text
- View/download PDF